Kyntra Bio Inc (NASDAQ:KYNB) Given Average Rating of “Moderate Buy” by Analysts

Kyntra Bio Inc (NASDAQ:KYNB) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $37.25.

A number of equities analysts have issued reports on KYNB shares. Rodman & Renshaw initiated coverage on shares of Kyntra Bio in a report on Tuesday, June 9th. They set a “buy” rating and a $30.00 price objective on the stock. Lake Street Capital initiated coverage on shares of Kyntra Bio in a research report on Thursday. They set a “buy” rating and a $41.00 price target on the stock. Weiss Ratings upgraded shares of Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 14th. Oppenheimer assumed coverage on shares of Kyntra Bio in a research report on Monday, July 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $43.00 price objective on shares of Kyntra Bio in a research note on Tuesday, September 1st.

Hedge Funds Weigh In On Kyntra Bio

An institutional investor recently bought a new position in Kyntra Bio stock. ADAR1 Capital Management LLC purchased a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned about 0.26% of Kyntra Bio at the end of the most recent quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

Kyntra Bio Trading Down 0.4%

NASDAQ KYNB opened at $7.07 on Friday. The firm has a market capitalization of $28.63 million, a P/E ratio of 0.16 and a beta of 1.06. The business has a fifty day simple moving average of $7.45 and a 200 day simple moving average of $7.18. Kyntra Bio has a 12 month low of $6.32 and a 12 month high of $12.58.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.